FILE 'CA' ENTERED AT 08:56:53 ON 20 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 14 Sep 2006 (20060914/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s epothilones and conjugate
          520 EPOTHILONES
        63645 CONJUGATE
L1         18 EPOTHILONES AND CONJUGATE

=> d l1 1-18

L1   ANSWER 1 OF 18  CA  COPYRIGHT 2006 ACS on STN
AN   144:404381  CA
TI   Salts of isophosphoramide mustard and analogs thereof as antitumor agents
IN   Morgan, Lee Roy
PA   Dekk-Tec Inc., USA
SO   U.S. Pat. Appl. Publ., 22 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 2006089333        A1    20060427    US 2005-257766          20051025
     WO 2006047575        A2    20060504    WO 2005-US38523         20051025
     WO 2006047575        A3    20060810
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
             NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
             SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
             YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRAI US 2004-622087P      P     20041025
     US 2005-672707P      P     20050418
OS   MARPAT 144:404381
```

L1 ANSWER 2 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 144:338265 CA
TI Catheter with balloon for the expansion of blood vessels carrying contrast agents and drugs
IN Sellin, Lothar; Han, Bock-Sun; Orlowski, Michael
PA Germany
SO Ger. Offen., 13 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 102004048265	A1	20060406	DE 2004-102004048265	20041004
PRAI DE 2004-102004048265		20041004		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:422204 CA
TI Processes for the preparation of chiral heptyne derivatives for the synthesis of epothilones
IN Platzek, Johannes; Petrov, Orlin; Willuhn, Marc; Graske, Klaus-Dieter; Skuballa, Werner
PA Schering Aktiengesellschaft, Germany
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005101950	A1	20051103	WO 2005-EP4492	20050421
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1589011	A1	20051026	EP 2004-90157	20040422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI EP 2004-90157	A	20040422		
US 2004-565849P	P	20040428		

OS CASREACT 143:422204; MARPAT 143:422204
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:311972 CA
TI Nanocell drug delivery system
IN Sengupta, Shiladitya; Zhao, Ganlin; Capila, Ishan; Eavarone, David; Sasisekharan, Ram
PA Massachusetts Institute of Technology, USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084710	A2	20050915	WO 2005-US6684	20050302
	WO 2005084710	A3	20060713		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005266067	A1	20051201	US 2005-70731	20050302
PRAI	US 2004-549280P	P	20040302		

L1 ANSWER 5 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:254027 CA
TI Polymeric water soluble antitumor agent conjugate comprising polyamino acid polymer and polyethylene glycol
IN Lee, William W.
PA Safeway Investments Ltd., Peop. Rep. China
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005079861	A2	20050901	WO 2005-US4377	20050211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2004-544694P	P	20040213		

L1 ANSWER 6 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:222473 CA
TI Epothilone compound conjugates, preparation methods, and therapeutic use
IN Klar, Ulrich; Willuda, Jorg; Menrad, Andreas; Bosslet, Klaus
PA Schering AG, Germany
SO Ger. Offen., 37 pp.
CODEN: GWXXBX
DT Patent
LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004004787	A1	20050818	DE 2004-102004004787	20040130
	WO 2005074901	A2	20050818	WO 2005-EP917	20050131
	WO 2005074901	A3	20060330		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

US 2005234247 A1 20051020 US 2005-45503 20050131
PRAI DE 2004-102004004787 A 20040130
US 2004-539977P P 20040130
OS MARPAT 143:222473

L1 ANSWER 7 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:211944 CA
TI Preparation of conjugates of epothilone derivatives as effectors with suitable biomolecules as recognition units
IN Klar, Ulrich; Willuda, Joerg; Menrad, Andreas; Bosslet, Klaus
PA Schering A.-G., Germany
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005074901	A2	20050818	WO 2005-EP917	20050131
WO 2005074901	A3	20060330		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

DE 102004004787 A1 20050818 DE 2004-102004004787 20040130
PRAI DE 2004-102004004787 A 20040130
US 2004-539977P P 20040130
OS MARPAT 143:211944

L1 ANSWER 8 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 142:404292 CA
TI Compositions and methods for increasing drug efficiency
IN Ballatore, Carlo; Castellino, Angelo John; Desharnais, Joel; Guo, Zijan; Li, Quing; Newman, Michael James; Sun, Chengzao
PA Dihedron Corporation, USA
SO PCT Int. Appl., 404 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005035003	A2	20050421	WO 2004-US31148	20040922
WO 2005035003	A3	20050818		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2005148534	A1	20050707	US 2004-948364	20040922
	US 2005187147	A1	20050825	US 2004-948707	20040922
PRAI	US 2003-505325P	P	20030922		
	US 2004-568340P	P	20040504		
	US 2004-581835P	P	20040622		
	US 2003-505033P	P	20030922		

OS MARPAT 142:404292

L1 ANSWER 9 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 142:254652 CA
TI Potentiation of the activation of high-molecular-weight prodrugs for therapeutic or diagnostic use
IN Trouet, Andre; Dubois, Vincent
PA Diatos, Fr.
SO Fr. Demande, 64 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2858936	A1	20050225	FR 2003-10114	20030822
	AU 2004268405	A1	20050310	AU 2004-268405	20040819
	CA 2536442	AA	20050310	CA 2004-2536442	20040819
	WO 2005021043	A2	20050310	WO 2004-FR2162	20040819
	WO 2005021043	A3	20060615		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	FR 2003-10114	A	20030822		
	WO 2004-FR2162	W	20040819		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 10 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 142:92195 CA
TI Anti-IGF-I receptor antibodies, fragments and conjugates for cancer research diagnosis and therapy
IN Singh, Rajeeva; Tavares, Daniel J.; Dagdigian, Nancy E.
PA Immunogen Inc., USA
SO U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S. Ser. No. 170,390.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004265307	A1	20041230	US 2003-729441	20031208
	US 2003235582	A1	20031225	US 2002-170390	20020614
	CN 1678633	A	20051005	CN 2003-813742	20030612

```
     US 2005186203          A1     20050825    US 2004-897406          20040723
     US 2005249728          A1     20051110    US 2004-932334          20040902
     AU 2004303792          A1     20050707    AU 2004-303792          20041207
     CA 2548065             AA     20050707    CA 2004-2548065         20041207
     WO 2005061541          A1     20050707    WO 2004-US38230         20041207
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     EP 1692176             A1     20060823    EP 2004-811082          20041207
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, BA,
             HR, IS, YU
PRAI US 2002-170390         A2     20020614
     US 2003-729441         A1     20031208
     WO 2004-US38230        W      20041207

L1   ANSWER 11 OF 18  CA  COPYRIGHT 2006 ACS on STN
AN   141:332039  CA
TI   Preparation of bioreductively activated prodrugs of antiproliferative
     agents
IN   Davis, Peter David; Naylor, Matthew Alexander; Thomson, Peter; Everett,
     Steven Albert; Stratford, Michael Richard Lacey; Wardman, Peter
PA   Angiogene Pharmaceuticals Limited, UK; Gray Laboratory Cancer Research
     Trust
SO   PCT Int. Appl., 45 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.             KIND   DATE        APPLICATION NO.         DATE
     ---------------        ----   --------    --------------------    --------
PI   WO 2004085421          A2     20041007    WO 2004-GB1330          20040326
     WO 2004085421          A3     20050324
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     AU 2004224070          A1     20041007    AU 2004-224070          20040326
     CA 2519901             AA     20041007    CA 2004-2519901         20040326
     EP 1613612             A2     20060111    EP 2004-723650          20040326
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
     CN 1791591             A      20060621    CN 2004-80013946        20040326
PRAI GB 2003-6907           A      20030326
     WO 2004-GB1330         W      20040326
OS   CASREACT 141:332039; MARPAT 141:332039

L1   ANSWER 12 OF 18  CA  COPYRIGHT 2006 ACS on STN
AN   141:38480  CA
```

TI Preparation of epothilone-saccharide conjugates for site specific delivery in the treatment of proliferative diseases
IN Bosslet, Klaus; Hess-Stumpp, Holger; Hoffmann, Jens; Klar, Ulrich; Rotgeri, Andrea
PA Schering A.-G., Germany
SO PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004050089	A1	20040617	WO 2003-EP13780	20031205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10256982	A1	20040624	DE 2002-10256982	20021205
AU 2003294796	A1	20040623	AU 2003-294796	20031205
US 2004167083	A1	20040826	US 2003-728098	20031205
EP 1581218	A1	20051005	EP 2003-785751	20031205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006510626	T2	20060330	JP 2004-556300	20031205
PRAI DE 2002-10256982	A	20021205		
US 2002-431197P	P	20021206		
WO 2003-EP13780	W	20031205		

OS MARPAT 141:38480
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 13 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 140:181251 CA
TI Preparation of new epothilone peptide effector conjugates for pharmaceutical use in the treatment of proliferative or angiogenesis associated disease processes
IN Berger, Markus; Siemeister, Gerhard; Klar, Ulrich; Willuda, Joerg; Menrad, Andreas; Bosslet, Klaus
PA Schering AG, Germany
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004012735	A2	20040212	WO 2003-EP8483	20030731
WO 2004012735	A3	20040527		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

	DE 10234975	A1	20040212	DE 2002-10234975	20020731
	DE 10305098	A1	20040819	DE 2003-10305098	20030207
	CA 2492437	AA	20040212	CA 2003-2492437	20030731
	AU 2003253365	A1	20040223	AU 2003-253365	20030731
	EP 1524979	A2	20050427	EP 2003-743752	20030731
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013043	A	20050614	BR 2003-13043	20030731
	JP 2006505627	T2	20060216	JP 2005-506073	20030731
	CN 1812785	A	20060802	CN 2003-818111	20030731
	NO 2005001038	A	20050406	NO 2005-1038	20050225
PRAI	DE 2002-10234975	A	20020731		
	DE 2003-10305098	A	20030207		
	US 2003-451673P	P	20030305		
	WO 2003-EP8483	W	20030731		

OS MARPAT 140:181251

L1 ANSWER 14 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 140:181250 CA
TI Preparation of new epothilone peptide effector conjugates for pharmaceutical use in the treatment of proliferative or angiogenesis associated disease processes
IN Berger, Markus; Klar, Ulrich; Siemeister, Gerhard; Willuda, Joerg; Menrad, Andreas; Bosslet, Klaus
PA Schering AG, Germany
SO Ger. Offen., 43 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10234975	A1	20040212	DE 2002-10234975	20020731
	CA 2492437	AA	20040212	CA 2003-2492437	20030731
	WO 2004012735	A2	20040212	WO 2003-EP8483	20030731
	WO 2004012735	A3	20040527		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003253365	A1	20040223	AU 2003-253365	20030731
	US 2005026971	A1	20050203	US 2003-631011	20030731
	EP 1524979	A2	20050427	EP 2003-743752	20030731
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013043	A	20050614	BR 2003-13043	20030731
	JP 2006505627	T2	20060216	JP 2005-506073	20030731
	CN 1812785	A	20060802	CN 2003-818111	20030731
	NO 2005001038	A	20050406	NO 2005-1038	20050225
PRAI	DE 2002-10234975	A	20020731		
	DE 2003-10305098	A	20030207		
	US 2003-451673P	P	20030305		
	WO 2003-EP8483	W	20030731		

OS MARPAT 140:181250

L1 ANSWER 15 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 140:99617 CA
TI Peptide conjugates with drugs as prodrugs for activation by tissue or

cell-specific proteinases
IN Madison, Edwin L.; Semple, Joseph Edward; Vlasuk, George P.; Kemp, Scott Jeffrey; Komandla, Mallareddy; Siev, Daniel Vanna
PA Corvas International, Inc., USA
SO U.S. Pat. Appl. Publ., 359 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004001801	A1	20040101	US 2002-156214	20020523
PRAI US 2002-156214		20020523		

OS MARPAT 140:99617

L1 ANSWER 16 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 137:274074 CA
TI Recombinant production of polyanionic polymers, and uses thereof as drug carriers for improvement of bioactivity and water-solubility
IN Leung, David W.; Bergman, Philip A.; Lofquist, Alan; Pietz, Gregory E.; Tompkins, Christopher K.; Waggoner, David W., Jr.
PA Cell Therapeutics Inc, USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002077036	A2	20021003	WO 2002-US8614	20020321
WO 2002077036	A3	20040129		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002169125	A1	20021114	US 2002-101487	20020320
AU 2002252429	A1	20021008	AU 2002-252429	20020321
US 2005118136	A1	20050602	US 2004-939988	20040914
PRAI US 2001-277705P	P	20010321		
US 2002-101487	A3	20020320		
WO 2002-US8614	W	20020321		

L1 ANSWER 17 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 134:56502 CA
TI Enantioselective Total Synthesis of Epothilones A and B Using Multifunctional Asymmetric Catalysis
AU Sawada, Daisuke; Kanai, Motomu; Shibasaki, Masakatsu
CS Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku Tokyo, 113-0033, Japan
SO Journal of the American Chemical Society (2000), 122(43), 10521-10532
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 134:56502
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 18 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 132:262172 CA
TI Use of neoangiogenesis markers for diagnosis and treatment of tumors
IN Krause, Werner; Muschick, Peter
PA Schering Aktiengesellschaft, Germany
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018439	A2	20000406	WO 1999-EP7198	19990929
	WO 2000018439	A3	20000914		
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, ES, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19845798	A1	20000413	DE 1998-19845798	19980929
PRAI	DE 1998-19845798	A	19980929		

=> d l1 1-18 an ab

L1 ANSWER 1 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 144:404381 CA
AB The invention discloses salts and compns. of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula A+··-OP(=O)(NHCH2CH2Y)NHCH2CH2X (A+ = ammonium species selected from protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; X, Y = leaving group). Also disclosed are methods for making such compds. and formulating pharmaceutical compns. thereof. Methods for administering the disclosed compds. to subjects, particularly to treat hyperproliferative disorders, also are disclosed.

L1 ANSWER 2 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 144:338265 CA
AB The invention concerns an expandable and contractable catheter with balloon that is provided with contrast agents and optionally with drugs. Contrast agents for computer tomog., nuclear magnetic tomog. or ultrasound imaging can be applied. Contrast agents contain barium, iodine, manganese, iron, lanthanum, cerium, praseodymium, neodymium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium and/or lutetium. Drugs are selected from the group of antiproliferative, anti-inflammatory, anti-phlogistic, cytostatic, cytotoxic and/or antithrombotic active substances. The invention concerns also concerns a method for introducing the contrast agents and drugs into the catheter and balloon by (a) placing the medical good in a vacuum chamber; (b) preparing of solns. with contrast agent and/or drug and placing it into cavities of the chamber; (c) applying vacuum; (d) nebulizing the solution using ultrasound and directing it onto the medical good for coating; (e) airing the chamber and removing the coated medical good.

L1 ANSWER 3 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:422204 CA
AB The invention relates to a new synthetic process for the production of key intermediates useful in the synthesis of epothilones or epothilone derivs. I [R1 = H, Me; R2 = heterocycle containing radical; R3 = H, alkyl], to certain compds. used to produce these key intermediates and to

a process to produce said compds. The intermediates used are alkynes II [R = H, (un)substituded alkyl; X1 = an oxygen protecting group] and III. The process for the preparation of intermediates IV comprises: (i) reaction of alkynol derivative V with RCHO in the presence of base to give III; (ii) oxidation of III to give II; and (iii) reduction of II to give IV. Alternatively, IV can be prepared via: (i) reaction of alkynol derivative V with RCOX (X = leaving group) to give II; and (ii) reduction of II to give IV.

L1 ANSWER 4 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:311972 CA
AB Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurol. diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antiangiogenic agent. A conjugate of lactide-glycolide copolymer and doxorubicin was prepared, nanocores prepared containing this conjugate, and a phospholipid matrix surrounded this nanocore.

L1 ANSWER 5 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:254027 CA
AB The present invention provides a conjugate comprising a chemotherapeutic agent (such as an antitumor drug) conjugated to a water soluble polyamino acid polymer, wherein the water soluble polyamino acid polymer is conjugated to a hydrophilic polymer such as polyethylene glycol. The present invention also provides a pharmaceutical composition comprising such a conjugate. Methods of making the pharmaceutical composition and methods of using the pharmaceutical composition for treating diseases and coating implantable medical devices are also provided.

L1 ANSWER 6 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:222473 CA
AB Conjugates of epothilones and epothilone derivs. (as effectors) with biomols. (as recognition units) are disclosed. Production involves reaction of an effector mol. with a suitable linker mol., followed by conjugation of the resulting product with a recognition mol., e.g. an antibody or antibody fragment. Also disclosed is the use of the conjugates of the invention for the treatment of proliferative or angiogenesis-associated processes.

L1 ANSWER 7 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 143:211944 CA
AB Conjugates of epothilones and epothilone derivs. (as effectors) with suitable biomols. (as recognition units) are described. Their production is carried out by the effectors being reacted with suitable linkers, and the compds. that are produced are conjugated to the recognition units. The pharmaceutical use of conjugates for treating proliferative or angiogenesis-associated processes is described. An examples linker prepared is (2S,5S)-[5-[2-[11-(2,5-dioxo-2,5-dihydropyrrol-1-yl)undecanoylamino]-3-phenylpropionylamino]-5--(4-hydroxymethylphenylcarbamoyl)pentyl]carbamic acid allyl ester. Effector-linker units and effector-linker recognition unit conjugates with antibodies were also prepared

L1 ANSWER 8 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 142:404292 CA
AB In one embodiment, provided herein are compns. and methods for increasing drug efficiency. In certain embodiments, the compns. contain conjugates having the formula: D-L-S wherein D is a drug moiety; L, which may or may not be present, is a non-releasing linker moiety; and S is a substrate for a protein or lipid kinase that is overexpressed, overactive or exhibits undesired activity in a target system.

L1 ANSWER 9 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 142:254652 CA
AB The invention discloses a modified form of a prodrug. The prodrugs of the invention include a bulky group, a spacer, a structure cleavable in the circulation, and a therapeutic agent or a marker. The spacer allows or facilitates the cleavage of the cleavable structure. Preparation of PEG-peptide-doxorubicin conjugates is included.

L1 ANSWER 10 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 142:92195 CA
AB Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-1 receptor.

L1 ANSWER 11 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 141:332039 CA
AB Title compds. I [wherein Ar = substituted heteroaryl bearing at least one NO2 or N3 group or (un)substituted 4,7-dioxo-3-indolyl, fused 1,4-dioxo-2,5-cyclohexadien-2-yl with hetero/aryl ring; R1, R2 = independently (un)substituted alk(en/yn)yl, aryl, COR3, or R1CR2 = (un)substituted heterocycloalkyl, carbocyclyl; L = (L')n; L' = -OC(:O)- or -OP(:O)(OR6)-; n = 0-1; X = O, S, NR7 or a single bond; R3 = OR4, NR4R5; R4, R5, R6, R7 = independently H, alkyl; or where R3 = NR4R5, NR4R5 = heterocycloalkyl; Dr = a moiety such that DrXH = cytostatic compound; and their pharmaceutically acceptable salts] were prepared as prodrugs which released antiproliferative agents upon bioreductive activation. Ten synthetic examples and five biol. examples are given. Thus, reacting 1-methyl-1-(5-nitrothiophen-2-yl)ethanol with combretastatin A4 in benzene in the presence of Bu3P/ADDP at 20° for 24 h gave II in 31% yield. II released combretastatin A4 at a G-value (number of mols. produced by 1 J of radiation energy) of 3.6•10-7 mol/J in the hypoxic environments of solid tumors.

L1 ANSWER 12 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 141:38480 CA
AB Conjugates of formula I [R1, R1a, R2, R2a, R3, R4. R4a = H, alkyl, aryl, arylalkyl; R1R1a, R2R2a, R4R4a = alkylene; R5 = H, alkyl, aryl, (substituted) CO2H, (substituted) CH2OH, CN, etc.; R6R7 = H, bond, O, NH, alkyl-N, CH2; D-E = CH2CH2, CH=CH, C.tplbond.C, CH(OH)-CH(OH), etc.; G = O, CH2; W = aromatic radical, CHO, etc.; Z = O, (substituted) OH; A-Y = O-CO, O-CH2, NH-CO, etc.; L1, L2, L3 = H, COCl, CSCl, (substituted) CO-O-phenoxy-saccharide, etc.] with epothilones and epothilone derivs. (as effectors) with suitable saccharides or saccharide derivs. (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compds. that are produced are conjugated to the effectors. The pharmaceutical use

of the conjugates for treating proliferative or angiogenesis-associated processes is described. Thus, II was prepared in several steps.

L1 ANSWER 13 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 140:181251 CA
AB Preparation of epothilone derivs., such as I (R2 = alkyl, alkenyl, alkynyl, aryl, etc.; L1, L2 = carboxyl, carbamoyl, carbonic linking group with a terminal group, such as maleimido, suitable for forming a sulfide link with a bio. mol.; L3 = heteroaryl, such as thiazol-4-yl; W = alkenylene linking group; or L3W = heteroaryl, such as benzothiazol-5-yl; X = O, bond), as effectors linked with suitable biomols. as recognition units was described (no biol. testing data was presented). Production of the epothilone conjugates was carried out by the effectors being reacted with suitable linkers, and the compds. that were produced were conjugated to biomol. recognition units. These conjugates are claimed for use in the treatment of proliferative or angiogenesis-associated disease processes, such as tumors, inflammatory diseases, neurodegenerative diseases, such as multiple sclerosis and Alzheimer's disease, and rheumatoid arthritis. Thus, epothilone derivative II [L1 = 3-(2,5-dioxo-2,5-dihydropyrrol-1-yl)-1-Pr, L2 = H] was prepared via a carbamoylation of silylated epothilone I (L1 = H, L2 = SiMe2CMe3) with 3-(2,5-dioxo-2,5-dihydropyrrol-1-yl)-1-propylisocyanate and subsequent desilylation.

L1 ANSWER 14 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 140:181250 CA
AB Preparation of epothilone derivs., such as I (R2 = alkyl, alkenyl, alkynyl, aryl, etc.; L1, L2 = carboxyl, carbamoyl, carbonic linking group with a terminal group, such as maleimido, suitable for forming a sulfide link with a bio. mol.; L3 = heteroaryl, such as thiazol-4-yl; W = alkenylene linking group; or L3W = heteroaryl, such as benzothiazol-5-yl; X = O, bond), as effectors linked with suitable biomols. as recognition units was described (no biol. testing data was presented). Production of the epothilone conjugates was carried out by the effectors being reacted with suitable linkers, and the compds. that were produced were conjugated to biomol. recognition units. These conjugates are claimed for use in the treatment of proliferative or angiogenesis-associated disease processes, such as tumors, inflammatory diseases, neurodegenerative diseases, such as multiple sclerosis and Alzheimer's disease, and rheumatoid arthritis. Thus, epothilone derivative II [L1 = 3-(2,5-dioxo-2,5-dihydropyrrol-1-yl)-1-Pr, L2 = H] was prepared via a carbamoylation of silylated epothilone I (L1 = H, L2 = SiMe2CMe3) with 3-(2,5-dioxo-2,5-dihydropyrrol-1-yl)-1-propylisocyanate and subsequent desilylation.

L1 ANSWER 15 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 140:99617 CA
AB Conjugates of peptides with drugs that are substrates of a tissue-specific proteinases that can be used to treat diseases associated with abnormal levels of the enzyme. The enzyme may be transmembrane serine proteinase, a urokinase, or an endotheliase. The conjugates are to be substrates for proteinases that may be cell- or tissue-specific. The drug moiety of the conjugate may be cytotoxic. The drug may be bound to the peptide by a labile linker that will eliminate itself after the preliminary hydrolysis.

L1 ANSWER 16 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 137:274074 CA
AB The invention provides a method for constructing a expression cassette that produce a polyanionic polymer that can be used as drug carriers to improve the bioactivity and water-solubility properties of a drug. The inventive method provides a monodispersed preparation of a recombinantly-produced polyanionic polymer that can be easily manipulated, such as lengthened. An active moiety may be chemical or recombinantly joined to a polyanionic polymer to increase its biol. half-life and/or solubility The instant invention also provides a method for targeting the delivery of a

polyanionic polymer conjugate or fusion protein to a specific cell type or tissue.

L1 ANSWER 17 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 134:56502 CA
AB An enantioselective total synthesis of epothilones A and B using multifunctional asym. catalysis such as a cyanosilylation of an aldehyde, an aldol reaction of an unmodified ketone with an aldehyde, and a protonation in the conjugate addition of a thiol to an α,β-unsatd. thioester has been achieved. Epothilones A and B were divided into fragment A (I), fragment B (II), and fragment C (III). A catalytic asym. synthesis of fragments A and B was accomplished using a catalytic asym. cyanosilylation as a key step. An enantiocontrolled synthesis of fragment C was achieved in two ways. One is the use of a direct catalytic asym. aldol reaction of an unmodified ketone with an aldehyde as a key step, and the other utilizes a catalytic asym. protonation in the conjugate addition of a thiol to an α,β-unsatd. thioester as a key step. Suzuki cross-coupling of fragment A with fragment C followed by Yamaguchi lactonization as key steps led to an enantiocontrolled synthesis of epothilone A. On the other hand, Suzuki cross-coupling of fragment B with fragment C followed by Yamaguchi lactonization accomplished an enantiocontrolled synthesis of epothilone B.

L1 ANSWER 18 OF 18 CA COPYRIGHT 2006 ACS on STN
AN 132:262172 CA
AB Neoangiogenesis markers (i.e. antibodies or receptors for e.g. vascular endothelial growth factor, placenta growth factor, acidic or basic FGF, transforming growth factor α or β, hepatocyte growth factor, insulin-like growth factor I, glycoprotein B61, protein LERK-1, flk-1 receptor, etc.) or partial sequences thereof and antiangiogenic compds. and factors such as paclitaxel, endostatin, fibronectin peptide, and fumagillin are conjugated with active agents such as chemotherapeutic agents, radiosensitizers, photosensitizers, antibodies, oligonucleotides, radioactive metal complexes, etc., which may be bound to carriers, for treatment of tumors. Likewise, neoangiogenesis markers may be conjugated to diagnostic agents such as MRI, radiog., ultrasound, or near-IR contrast agents for tumor diagnosis. Thus, N',N',N''',N'''-tetrakis(tert-butoxycarboxymethyl)-N''-(hydroxycarboxymethyl)diethylenetriamine was converted to its N-hydroxysuccinimide ester, coupled to a Thy-1 antibody, complexed with 186Re, and injected i.v. into rabbits for detection of implanted VX2 tumors by scintigraphy with a gamma camera.